Centessa prices upsized $225M ADS offering at $14.75/ADS; net proceeds ~$211M

Centessa Pharmaceuticals plc

Upsized offering: 15,254,237 ADSs at $14.75/ADS, gross proceeds ~$225M.
Underwriters have 30-day option for additional 2,288,135 ADSs.
Net proceeds ~$211M (or ~$242.7M with full overallotment) to fund product development and corporate.
Company expects existing cash plus net proceeds to fund operations into mid-2027.
Offering expected to close Sept 16, 2024; Goldman Sachs and Leerink Partners lead underwriters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.